UPDATE: Heptares licenses its HTL-1071 to AstraZeneca

6 August 2015

UK-based biotech company Heptares Therapeutics, a subsidiary of Japan’s Sosei Group (TYO: 4565), has entered into a licensing agreement with AstraZeneca (LSE: AZN) under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialize the adenosine A2A receptor antagonist HTL-1071.

AstraZeneca will focus on exploring the candidate and any additional compounds across a range of cancers, including as a combination therapy with its existing immunotherapy compound.

By stimulating A2A receptors, adenosine stops T-cells within the immune system from proliferating and reduces their ability to destroy cancer cells. Blocking A2A receptors can promote the anti-cancer response of T-cells in the tumor microenvironment.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK